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A capillary zone electrophoresis method for pravastatin determination was developed and vali-
dated. Rapid migration of negatively charged pravastatin molecule was obtained in alkaline
buffer by the application of electric field of 30 kV. Influence of the pH value and ionic strength
of running buffer, applied voltage and capillary temperature on mobility and sensitivity was
evaluated. Detection wavelength was set to 237 nm. The method was applied to the determina-
tion of the drug in pharmaceutical dosage form. Pravastatin is a d-hydroxy acid, which is prone
to lactonize and epimerize in a pH-dependent manner. Micellar electrokinetic chromatographic
approach was chosen to develop a method able to separate pravastatin and its degradation
products in acidic media. The proposed method allows baseline separation of hydroxy acid and














Pravastatin is a cholesterol-lowering compound that com-
petitively inhibits the microsomal enzyme 3-hydroxy-3-
methylglutaryl-co-enzyme A (HMG-CoA) reductase, a
rate-limiting enzyme in the cholesterol biosynthetic path-
way. Although the HMG-CoA reductase inhibitors (sta-
tins) are structurally related, only pravastatin has a hy-
droxyl substituent on the hexahydronaphthalene nucleus
(Figure 1). Pravastatin is characterized as one of the best
statins due to the hydroxyl group which causes higher
hydrophilicity than other statins.1
Pravastatin possesses an alkyl chain terminated with
a carboxylic acid group and bearing two hydroxyl groups
at the b and d positions with respect to the carboxylic
acid group. The carboxylic acid group and the hydroxyl
group at the d position are prone to lactonize, as shown
in Figure 1. Lactonizable compounds such as statins may
exist in the free acid form or the lactone form or as an
equilibrium mixture of both forms.2 Lactonization causes
processing difficulties in the manufacture of statin drugs.
Consequently, great care must be exercised when han-
dling lactonizable compounds in order to isolate them in
high yields.
All statins share an HMG-like pharmacophore, which
may be present in the active hydroxy-acid form or in the
inactive prodrug lactone form. In vivo, prodrug lactones
are enzymatically hydrolyzed to their hydroxy-acid phar-
macophores.3 Pravastatin is administered to patients in its
active form as the hydroxyl acid sodium salt. The drug
exists in solution with its lactone equilibrium product in
a pH-dependent manner. At acidic pH, the hydroxy acid
form of pravastatin can reversibly lactonize. Additional-
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ly, pravastatin is also susceptible to an isomerization re-
action at acidic pH, which is relatively rapid.4 The C-6
position is bis-allylic and, hence, the C-6 atom is prone
to epimerize.
Statins are now among the most frequently pre-
scribed drugs for reducing LDL cholesterol and triglyce-
ride levels in the blood stream of patients at risk of cardio-
vascular disease.5 For this reason, rapid and effective
ways for the determination of these drugs are desirable.
In addition, treatment with statins is very long and thus
the purity of these drug substances is of great impor-
tance. Development of simple and selective methods for
monitoring their potential impurities is highly required.
Several HPLC methods for the analysis of pravastatin have
been developed using UV,6–9 fluorescence10 and MS-MS
detection.11–16 Voltammetry was also used for drug quan-
titation.17 However, capillary electrophoretic methods pro-
posed for the determination of pravastatin are scarce.18
Micellar electrokinetic chromatography (MEKC) has been
used for its determination in production media.19 Capil-
lary electrophoresis has been applied to the screening of
anionic impurities in bulk drug and determination of pra-
vastatin pKa value.20,21 The official method in assay pro-
cedures of pravastatin listed in the European Pharmaco-
poeia and its pharmaceutical product described in USP is
the HPLC method with UV detection (retention time about
21 min).22
Application of capillary zone electrophoresis (CZE)
by the pharmaceutical industry is mainly due to the wide
range of possible benefits that may be obtained com-
pared to the well-established and widely used HPLC tech-
nique. Principal advantages include improvements in cost
efficiency and solvent avoidance. Capillary electropho-
resis may be easier and faster for a number of analyses.
The present work was aimed at developing a reliable
and simple method with a short run time for the determi-
nation of pravastatin using CZE. The proposed method
has been applied to determination of the drug in a phar-
maceutical formulation. MEKC approach was chosen to
develop a method able to separate the drug and its in-
terconversion products in acidic media.
EXPERIMENTAL
Materials
Pravastatin sodium, kindly supplied by Pliva (Zagreb, Croa-
tia), was used without any purification. The quality of the
drug is high enough to comply with the European Pharma-
copoeia (98.1 %). Stock solution was prepared in water at a
concentration of 0.1 mg mL–1 and stored at 4 °C in a refrig-
erator.
Standard solutions were prepared daily by diluting the
stock solution with water just before use in a concentration
range from 1 to 100 µg mL–1. Water used for the prepara-
tion of standard solutions and running buffers was purified
by a Milli-Q system. All the other chemicals used were of
analytical reagent grade quality (Merck or Sigma).
Apparatus
Capillary electrophoresis experiments were performed on an
Agilent CE system (Agilent Technologies, Waldbronn, Ger-
many), equipped with a diode array detector. The data were
collected using the 3DCE/MSD ChemStation software ver.
A 10.02. Uncoated fused-silica capillaries (Agilent Techno-
616 B. NIGOVI] AND I. VEGAR

















































Figure 1. Structures of pravastatin (1), pravastatin lactone (2), C-6-epimer of pravastatin (3) and its lactone form (4).
logies) of 48.5 cm total length (effective length to detector
40 cm) and 50 µm internal diameter were used. An align-
ment interface, containing an optical slit matched to the in-
ternal diameter, was employed and the detection wavelength
was adjusted to 237 nm. The applied voltage was held con-
stant at different values ranging within 10–30 kV. All the
electrophoretic runs were carried out at constant tempera-
ture. The temperature inside the capillary cartridge was
maintained within the 20–40 °C range.
Analytical Procedure
At the beginning of each working day, the capillary was
rinsed with 0.1 mol L–1 NaOH for 5 min under high pres-
sure, followed by rinsing with water (10 min) and running
buffer (5 min). Repeatability of migration times was found
to be dependent on the rinse procedure. The capillary was
flushed between the runs with BGE for 5 min to ensure as-
say reproducibility. As electrolysis of the background elec-
trolyte solutions can change the electroosmotic flow, which
leads to poor quantitative assays, the running buffer was re-
placed with a fresh electrolyte after three injections.
Samples were injected into the capillary on the anodic
side by 50 mbar pressure for 4 s. Before the injection into
the CE system, each solution (sample solutions and running
buffer) was subjected to filtration through 0.2 µm Acrodisc
GHP filters (Gelman, Ann Arbor, USA). Electrophoresis
was carried out by applying high voltage to the capillary,
with the cathode being at the detector end.
The BGE solutions used for CZE were prepared from
sodium tetraborate by adjusting to the desired pH with 0.1
mol L–1 hydrochloric acid or 0.1 mol L–1 sodium hydroxide.
Sample solution of pravastatin for monitoring its deg-
radation products using capillary electrophoresis was pre-
pared at a concentration of 75 µg mL–1 in acidic media
(pH = 2). Borate buffer (25 mmol L–1, pH = 9.3) with 25
mmol L–1 sodium dodecyl sulphate (SDS) was used for mi-
cellar electrokinetic chromatographic measurements.
Pharmaceutical Formulation Analysis
Pravastatin tablets (Pravachol, 20 mg) were purchased from
the local market. Pravachol contains the following excipi-
ents: croscarmellose sodium, lactose, magnesium oxide,
magnesium stearate, microcrystalline cellulose, povidone
and yellow ferric oxide. A powdered sample of drug formu-
lation equivalent to the average weight of one tablet was
transferred into a 50 mL calibrated flask and purified water
was added (30 mL). The mixture was sonicated for 5 min to
provide complete dissolution and was made up to the mark
with purified water. Appropriate solutions were prepared by
taking suitable aliquots of the clear supernatant and diluting
them with purified water to give a final analyte concentra-
tion (20, 35, 50 and 65 µg mL–1). Tablet sample solutions
were then analyzed in the same way as standard solutions
by the proposed CZE method. Solutions were filtered
through 0.2 µm filters before injection to the CE system.
For recovery experiments, known quantities of pure drug
were added to the different pre-analyzed samples of a com-
mercial formulation. Total amount of the drug was then de-
termined using the proposed CZE method and the amount
of the added drug was calculated by the difference.
RESULTS AND DISCUSSION
Capillary Zone Electrophoresis
In an attempt to find the suitable pH value and ionic
strength for the running buffer and considering the mo-
lecular structure of pravastatin that provides information
on its acido-base properties, the influence of pH and buf-
fer ionic strength on mobility, sensitivity and speed were
carefully evaluated. Buffer pH has an influence on the
degree of ionization of the molecules, their electropho-
retic mobility as well as on the control of the electroos-
motic flow. Pravastatin structure suggests that a capillary
zone electrophoresis method could be used under alka-
line conditions for determination of this drug. As report-
ed in the literature,23 pravastatin has a pKa value of 4.2.
The drug is completely in the anionic form above pH = 6.
Therefore, the working pH has to be above this pH value,
so that pravastatin can be ionized and analyzed using
CZE. On the other hand, the alkaline buffer will gener-
ate strong electroosmotic flow, allowing for shorter anal-
ysis time. Borate buffer solutions in the pH range be-
tween 7.5 and 10 were investigated. Within the studied
pH range, the best results were at pH = 9.3, which pro-
vided a good compromise among the migration time,
peak shape and sensitivity of the method (Figure 2).
The effect of ionic strength of the buffer on analysis
time was assessed at a constant pH of 9.3. As the con-
centration was changed from 20 to 30 mmol L–1, a small
increase in pravastatin migration time was obtained. It is
suggested that this effect is related to lower electroosmo-
tic flow, resulting from a decrease of the zeta potential at
the capillary wall-solution interface.24 Efficiency of the
assay, expressed as the number of theoretical plates, was
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Figure 2. Effect of running buffer pH on the migration time (circles)
and peak area (squares) of pravastatin (50 mg mL–1). Operating
conditions: 25 mmol L–1 borate buffer, voltage 30 kV, 20 °C, detec-
tion wavelength 237 nm, hydrodynamic injection 50 mbar, 4 s.
calculated using the formula N = 5.545 (l/w)2, where N =
number of theoretical plates, l = effective capillary length
and w = peak width. A plot of N vs. borate concentration
was constructed and 25 mmol L–1 was selected as the op-
timum borate concentration for running buffer with a max-
imum of 232 187 theoretical plates obtained. Addition of
SDS as surfactant in the running buffer was also studied.
Introduction of anionic detergent SDS (25 mmol L–1) into
borate buffer increases the migration time of pravastatin.
This is the reason for choosing CZE instead of micellar
electrokinetic chromatography for determination of pra-
vastatin in bulk form and in pharmaceuticals.
The effect of the applied voltage on pravastatin mi-
gration time was examined over the range 10–30 kV. Us-
ing 25 mmol L–1 borate buffer at pH = 9.3, the increase
of the applied voltage led to shorter migration time. As
expected, increasing the applied voltage caused an in-
crease in electroosmotic flow, leading to shorter analysis
time of negatively charged pravastatin molecules. Prava-
statin determination was performed at a voltage of 30 kV;
the current was 45–47 µA under these conditions.
The temperature inside the capillary cartridge also af-
fects solute mobility and the electroosmotic flow. In ad-
dition, capillary temperature control is extremely impor-
tant for assay reproducibility. Influence of temperature
on the analysis was investigated for 20, 25, 30, 35 and
40 °C. On increasing the temperature, the migration time
of pravastatin as well as the peak area decreased. The
20 °C temperature was chosen for suitable analysis time
and good sensitivity.
Through the experiments described above, optimum
conditions for the determination of pravastatin were de-
fined. Strong UV absorption at 237 nm allows direct on-
-line detection by CZE. A typical electropherogram of
pravastatin standard solution is given in Figure 3A. The
strong electric field and alkaline running buffer generate
strong electroosmotic flow, allowing drug determination
within 2.55 min. Pravastatin retention time is about 21 min
in the assay procedure listed in Ph. Eur. using the HPLC
with UV detection.22 Relatively short analysis time is the
main advantage of the CZE method. Furthermore, the
proposed method offers several advantages over HPLC,
including low consumption of reagents and solvents, small
sample size, simplicity and inexpensive capillaries.
Method Validation
After development, experiments were carried out to
evaluate the validity of the method for pravastatin deter-
mination in raw material and in tablets. In the developed
CZE method, linearity of the detector response was es-
tablished for pravastatin concentration ranging from 5 to
75 µg mL–1. The regression equation of the calibration
curve was y = 187.64 x – 0.036 with the correlation co-
efficient of 0.997 (n = 6). The detection limit and the
quantification limit were calculated from the calibration
curve using the equations: LOD = 3s/m and LOQ = 10s/m
(where s is the standard deviation of the intercept and m
is the slope of the calibration curve).25 LOD and LOQ
were found to be 0.5 and 1.8 µg mL–1, respectively. Due
to the small diameter of the capillary, volumes of the or-
der of nanoliters were injected. For the same reason, the
light path at the on-capillary detector window is very
short, reducing the signal produced by the sample. There-
fore, the detection and quantitation limits are approxima-
tely three orders of magnitude higher than LODs and
LOQs for some chromatographic methods reported.26
However, the detection sensitivity achieved using max-
ima at wavelengths 237 nm was sufficient for drug quan-
titation in commercially available formulations.
Method precision was determined by measuring re-
peatability or intra-day precision and inter-day precision
of migration times and peak area. Multiple injections
(n = 6) of the same pravastatin sample solution were car-
ried out to demonstrate the repeatability. The RSDs of
migration times were found to be 0.41 % at the 5 µg mL–1
level and 0.78 % at the 25 µg mL–1 level. Replicate in-
jections of the lowest level of concentration among the
calibration graph solutions provided the RSD of the
peak area of 1.68 %. Inter-day precision was also evalu-
ated over three different days with newly prepared run-
ning buffer and samples by performing six successive
injections of four replicate samples on each day. RSDs
< 1.1 % were obtained for the inter-day migration times.
Three different pravastatin concentrations in the linear
range were analyzed in six independent series on the
same day and six successive days. The data evaluated by
the use of calibration plots are summarized in Table I.
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10.0 10.09±0.14 1.39 0.90 10.14±0.21 2.07 1.40
25.0 24.89±0.21 0.84 –0.44 24.76±0.23 0.93 –0.96
50.0 50.04±0.47 0.94 0.08 49.95±0.39 0.78 –0.10
(a) Mean of five determinations ± SD, (b) RSD, relative standard deviation, (c) Bias %, [(found – added) / added] × 100
Stability of standard solutions was maintained by
leaving the pravastatin solutions (50 µg mL–1) in a tight-
ly closed volumetric flask in the refrigerator at 4 °C. The
solutions were measured at 6 h intervals for 2 days. They
were found to be stable for the period studied.
Analytical Application
In order to establish the potentiality of the developed
method, a pharmaceutical dosage form of pravastatin
was assayed. It was noticed in formulation samples that
excipients did not interfere with the peak of interest un-
der the separation conditions (Figure 3B). In addition,
the peak purity evaluation revealed that the UV spectra
of different parts of the peak were identical, indicating
homogeneity of the pravastatin peak in formulation sam-
ples. The peak purity factor was found to be 999.6 for
pravastatin in the tablet solution. This is a measure of sim-
ilarity in the shape of the spectra. Accuracy of the meth-
od, regarded as the closeness of agreement between the
claimed content of tablets and the found value, was 99.2 %
(RSD = 1.1 %, n = 5). Accuracy was also verified by re-
covery studies analyzing samples fortified by known
quantities of the drug. The assay results for pravastatin
formulation are given in Table II. Application of CZE to
pravastatin determination in a pharmaceutical prepara-
tion resulted in acceptable percent recoveries; therefore,
the developed CZE method can be used as an alternative
method for the analysis of pravastatin in bulk form and
in pharmaceuticals. The best working concentrations are
from 25–35 µg mL–1. Considering the data relating to the
reproducibility in peak area and short and reproducible
migration time, it is apparent that the proposed CZE
method is a very promising alternative method for the
determination of this drug.
Micellar Electrokinetic Capillary Chromatography
Pravastatin is a d-hydroxy acid, which is prone to lacto-
nize and epimerize in a pH-dependent manner. The hy-
droxy acid form of pravastatin can reversibly lactonize
at acidic pH, so the drug exists in solution with its lac-
tone equilibrium product. It was found in the literature
that the extent of lactonization is < 6 % over the 30-min
experimental period at pH = 2.27 Pravastatin is also sus-
ceptible to an isomerization reaction at acidic pH, which
is relatively rapid.4,28 The above mentioned interconver-
sion compounds of pravastatin represent its related im-
purities listed in Ph. Eur and are also potential biotrans-
formation products.4,22
In capillary electrophoresis, the selectivity of the
method is fundamentally based on charge-to-volume ra-
tios. The free hydroxyl acid and the lactone forms of
pravastatin have different polarities; therefore, capillary
electrophoresis can be a procedure with totally different
selectivity of these interconversion forms present in aci-
dic solution. The MEKC method was developed for the
separation of pravastatin and its degradation products in
acidic media. Introduction of SDS in the background
electrolyte solutions plays a key role for the separation
of negatively charged hydroxyl acid forms and neutral
lactone species that migrate at the same rate as the EOF
in the CZE method. Separation of neutral pravastatin lac-
tone from each other requires partitioning into charged
micelles that migrate at a different rate from the EOF.
Aqueous samples of the drug were acidificated (pH =
2) and analyzed immediately and after set intervals. De-
gradation at pH = 2 was monitored for a period of 4 hours
at room temperature. To check the repeatability of drug
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Figure 3. Electropherogram of pravastatin in 25 mmol L–1 borate
buffer, pH = 9.3, (A) in standard solution (25 mg mL–1) and (B) in
tablet solution (25 mg mL–1 pravastatin). Operating conditions: volt-
age 30 kV, 20 °C, detection wavelength 237 nm, hydrodynamic
injection 50 mbar, 4 s.
TABLE II. Determination of pravastatin in a pharmaceutical formu-
lation







(a) Mean of five determinations
degradation, a pravastatin solution was divided into
three aliquots. Each aliquot was acidified and analyzed.
The presence of 25 mmol L–1 SDS in the running borate
buffer at pH = 9.3 produces very good separation of deg-
radation products. A series of SDS concentrations were
evaluated for their effect on the efficiency of degrada-
tion product resolution and migration time. The migra-
tion time of the compounds increased with an increase in
SDS concentration. Further decrease in SDS concentra-
tion resulted in decreased efficiencies. Choosing a 25
mmol L–1 borate buffer, pH = 9.3, addition of 25 mmol
L–1 SDS, applied voltage of 30 kV, and temperature of
20 °C resulted in a complete separation analysis of pra-
vastatin and its degradation products in less than 6.5 min.
Under these conditions, the recorded current was lower
than 60 µA. The peak purity of separated compounds
was obtained by overlaying the spectra captured at the
apex, up and down the slope, using a diode-array detec-
tor, and no interference was noted. The recorded on-line
spectra of the peaks of degradants were found to have
the absorption maximum almost at the same wavelength
as the pravastatin molecule.
Pravastatin molecule passed the detector window in
3.32 min with addition of 25 mmol L–1 SDS used for the
MEKC method. Significant decrease of pravastatin con-
centration at pH = 2 was observed within 2 min (Figure
4A). At the same time, new peaks at 2.93 min and 6.19
min were observed. Negative charge on the epimerized
compound in alkaline buffer and the literature data19,27
suggest that the first peak could be attributed to the C-6
epimer of pravastatin. Epimerization was relatively rap-
idly observed but the equilibrium of interconversion pro-
ducts was established after 70 min. The amount of pra-
vastatin decreased by about 40 % within 20 min after
sample acidification and new peaks at 2.82 and 5.44 min
were observed (Figure 4B). Since lactone forms are de-
void of any ionizable moiety, the slowest migrating
compound can be attributed to neutral pravastatin lactone,
which should have the highest affinity for the negatively
charged micelles. We have therefore concluded that the
degradation products observed with UV detection at
6.19 min could be assigned to pravastatin lactone.27
Slower formation of lactone forms compared to the epi-
merization rate is also in agreement with literature data.4,28
The peak at 5.44 min which appeared later, after 15 min
of degradation time, could be attributed to the C-6 epi-
mer of pravastatin lactone. Its peak area was found to in-
crease with increasing concentration of the C-6 epimer
of pravastatin over time (Figure 4C), so conversion of the
C-6 epimer of pravastatin to its lactone form was assum-
ed. Pravastatin and its C-6 epimer are fully charged at
pH = 9.3, thus bearing a negative charge, which causes
some degree of repulsion between the drug molecules and
negatively charged micelles. The C-6 epimer of prava-
statin elutes first suggesting, in agreement with previously
reported data, that the partition coefficient between SDS
micelles and buffer solutions is different from that of prava-
statin.19 Both negatively charged analytes exhibited mi-
gration toward the cathode due to high electroosmotic
velocity.
The proposed capillary electrophoresis method al-
lows baseline separation of pravastatin and all its degra-
dation products in acidic media. Separation time of 6.5
min was sufficient for the analysis. Thus the developed
MEKC method has a shorter runtime compared to the
reported HPLC method for separation of pravastatin re-
lated impurities using UV detection.22 Peak identity was
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Figure 4. Separation of pravastatin (75 mg mL–1) exposed to aci-
dic media (pH = 2) and its degradation products obtained after
(A) 2 min, (B) 20 min and (C) 80 min. Separation conditions:
25 mmol L–1 borate buffer, pH = 9.3, 25 mmol L–1 SDS, voltage
30 kV, 20 °C, detection wavelength 237 nm, hydrodynamic injec-
tion 50 mbar, 4 s.
studied by the spectra recorded using a diode-array de-
tector. However, the UV spectra of pravastatin, C-6
epimer of pravastatin and pravastatin lactones do not dif-
fer significantly. The exact identity of separated peaks
could be known by comparing the migration time with
each degradation product, because UV spectra of all
compounds are very similar, or by mass detection, which
will be the subject of further investigations. Analysis by
MEKC coupling with mass spectrometry could confirm
the assumption described above. Although the limit of
quantitation of the pravastatin assay using CZE is still
high, it is reasonable to predict that the MEKC method
could be used for evaluation and quantitation of its deg-
radation products at a low level by capillary electropho-
resis using more sensitive mass spectrometric detection.
CONCLUSIONS
A capillary zone electrophoresis method was developed
for determination of pravastatin. The applied voltage of
30 kV and alkaline running buffer, pH = 9.3, generate
strong electroosmotic flow that enables determination of
a fully charged drug molecule within 2.5 min. Applica-
tion of the CZE to pravastatin determination in a phar-
maceutical dosage form resulted in acceptable deviation
from the stated concentration. Therefore, the developed
CZE method can be used as an alternative method for the
quantitation of pravastatin in bulk form and in pharma-
ceuticals.
Micellar electrokinetic chromatographic approach was
chosen to develop a method able to separate the drug and
its degradation products in acidic media. The proposed
method allows baseline separation of pravastatin, C-6
epimer of pravastatin and their lactone forms that appear
as interconversion products depending on the pH value.
The migration times of degradation compounds ranged
from 2.8 to 6.2 min.
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SA@ETAK
Odre|ivanje pravastatina i odjeljivanje njegovih razgradnih produkata
kapilarnom elektroforezom
Biljana Nigovi} i Ivana Vegar
Razvijena je i validirana metoda kapilarne zonske elektroforeze za odre|ivanje pravastatina. Dobivena je
brza pokretljivost negativno nabijenih molekula pravastatina u lu`natom puferu primjenom elektri~nog polja od
30 kV. Istra`ivan je utjecaj pH i ionske jakosti pufera, primijenjenog napona i temperature u kapilari, na po-
kretljivost analita i osjetljivost metode pri valnoj duljini detekcije 237 nm. Metoda je primijenjena za odre|i-
vanje lijeka u farmaceutskom dozirnom obliku. Pravastatin je d-hidroksi kiselina koja je sklona laktonizaciji i
epimerizaciji u ovisnosti o pH vrijednosti medija. U razvoju metode odjeljivanja pravastatina i njegovih raz-
gradnih produkata u kiselom mediju kori{tena je micelarna elektrokineti~ka kromatografija. Predlo`ena metoda
omogu}ava odjeljivanje hidroksi kiselinskih i neutralnih laktonskih oblika lijeka koji se pojavljuju kao produkti
prijelaza ovisno o pH vrijednosti.
622 B. NIGOVI] AND I. VEGAR
Croat. Chem. Acta 81 (4) 615¿622 (2008)
